Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,003 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Platelets Clear all
Completed Not applicable Interventional

Platelet Rich Plasma (PRP) for Vulvar Lichen Sclerosus

NCT03045172
View directory record Official record
Conditions
Lichen Sclerosus of Vulva
Interventions
Platelet Rich Plasma, Placebo
Biological · Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 27, 2026, 6:22 PM EDT
Recruiting Early Phase 1 Interventional

Sildenafil to Reduce Vascular Remodeling During Left Ventricular Assist Device Support

NCT06510322
View directory record Official record
Conditions
Vascular Diseases
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 27, 2026, 6:22 PM EDT
Terminated Phase 2 Interventional Results available

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

NCT03606642
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Stent Placement
Interventions
Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
Drug · Device
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
75 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 27, 2026, 6:22 PM EDT
Completed Not applicable Interventional Results available

COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT

NCT01925794
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
COBRA PzF
Device
Lead sponsor
CeloNova BioSciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
22
States / cities
Bakersfield, California • Miami Beach, Florida • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 27, 2026, 6:22 PM EDT
Completed Phase 3 Interventional Results available

In Vivo Effects of Fibrinogen Concentrate (FC) Versus Cryoprecipitate on the Neonatal Fibrin Network Structure After Cardiopulmonary Bypass (CPB)

NCT03932240
View directory record Official record
Conditions
Hemostasis
Interventions
Fibrinogen Concentrate (FC), Cryoprecipitate
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Day to 30 Days
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 27, 2026, 6:22 PM EDT
Terminated Phase 2 Interventional Results available

X-82 to Treat Age-related Macular Degeneration

NCT02348359
View directory record Official record
Conditions
Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD, Macular Degeneration, Age-related, 10, Eye Diseases, Retinal Degeneration, Retinal Diseases
Interventions
X-82, Anti-VEGF, Placebo
Drug
Lead sponsor
Tyrogenex
Industry
Eligibility
50 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
35
States / cities
Tucson, Arizona • Beverly Hills, California • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 27, 2026, 6:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

PAR Regulation of Platelet Function in Diabetic Patients

NCT00855374
View directory record Official record
Conditions
Coronary Artery Disease, Acute Coronary Syndrome, Diabetes, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 27, 2026, 6:22 PM EDT
Not listed No phase listed Observational

Prevalence and Level of Thienopyridine Resistance Seen in a Contemporary Percutaneous Coronary Intervention or Coronary Artery Bypass Graft Population

NCT01408927
View directory record Official record
Conditions
Increased Drug Resistance
Interventions
Thienopyridine resistance testing, Aspirin resistance testing, Genetic polymorphism assessment
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 27, 2026, 6:22 PM EDT
Recruiting Phase 2 Interventional

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

NCT06261060
View directory record Official record
Conditions
Familial Platelet Disorder, Hematopoietic
Interventions
Sirolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 27, 2026, 6:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Delivering Transcutaneous Auricular Neurostimulation to Regulate Platelet Activity in Healthy Human Subjects

NCT05977946
View directory record Official record
Conditions
Hemostasis, Blood Biomarkers
Interventions
Volta System
Device
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 27, 2026, 6:22 PM EDT
Terminated Phase 2 Interventional Results available

Vandetanib to Treat Advanced Kidney Cancer

NCT01372813
View directory record Official record
Conditions
Advanced Clear Cell Renal Carcinoma
Interventions
vandetanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Oct 27, 2026, 6:22 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer

NCT01268059
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Carboplatin, Paclitaxel, MEDI-575
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Fountain Valley, California • Oxnard, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 27, 2026, 6:22 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy of Ellacor® Micro-coring® Following Best Practices on Technique and Post-Procedural Care

NCT07260578
View directory record Official record
Conditions
Best Practices, Ellacor, Micro-coring Post Care, Ellacor Post Care
Interventions
ellacor Micro-Coring Technology
Device
Lead sponsor
Cytrellis Biosystems, Inc.
Industry
Eligibility
45 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Miami, Florida • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 27, 2026, 6:22 PM EDT
Not listed Not applicable Interventional

BIOlogic Augmented Repair of Complex Anal Fistula Using Acellular Matrix and/or Autologous Platelet-rich Plasma

NCT05805449
View directory record Official record
Conditions
Anal Fistula
Interventions
Surgery, Platelet-rich plasma (PRP), Matrix
Procedure · Other · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 27, 2026, 6:22 PM EDT
Completed Not applicable Interventional

Platelet Function Analysis in Head Trauma: ASA/Plavix

NCT01534117
View directory record Official record
Conditions
Head Injury Trauma Blunt
Interventions
Platelets, DDAVP
Biological · Drug
Lead sponsor
Chang, Steve S., M.D.
Individual
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Oct 27, 2026, 6:22 PM EDT
Completed Phase 1 Interventional

Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

NCT00334438
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, yttrium Y 90 ibritumomab tiuxetan, Indium 111 ibritumomab tiuxetan
Biological · Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Hackensack, New Jersey • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 27, 2026, 6:22 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Cascade PRFM Study: The Evaluation of Cascade Platelet-Rich Fibrin Matrix (PRFM) on Rotator Cuff Healing

NCT00198185
View directory record Official record
Conditions
Rotator Cuff, Tendon Injuries
Interventions
Placement of Platelet Rich Fibrin Matrix During Arthroscopic Rotator Cuff Surgery
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Oct 27, 2026, 6:22 PM EDT
Recruiting Not applicable Interventional

Trial for Treating Painful Degenerative Disc Disease

NCT05287867
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP), Sham procedure
Biological · Other
Lead sponsor
Regenexx, LLC
Industry
Eligibility
25 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Broomfield, Colorado • Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 27, 2026, 6:22 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer

NCT03955471
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Dostarlimab
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Scottsdale, Arizona • Duarte, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 27, 2026, 6:22 PM EDT
Recruiting No phase listed Observational

A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction

NCT05332262
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Assessment of platelet reactivity, Troponin measurement
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 27, 2026, 6:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR

NCT01611298
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Interventions
Tetanus
Biological
Lead sponsor
Robert Krance
Other
Eligibility
3 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 27, 2026, 6:22 PM EDT
Completed Phase 4 Interventional Results available

Platelet-rich Plasma vs. Hyaluronic Acid for Glenohumeral Osteoarthritis

NCT02984228
View directory record Official record
Conditions
Osteoarthritis, Shoulder Pain
Interventions
PRP, Hyaluronic Acid, Ultrasound
Biological · Drug · Device
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 100 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 27, 2026, 6:22 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Rh-PDGF vs EMD for Treatment of Intra-bony Defects

NCT05442034
View directory record Official record
Conditions
Intrabony Periodontal Defect
Interventions
growth factors to help in regeneration
Biological
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 27, 2026, 6:22 PM EDT
Not yet recruiting Not applicable Interventional

Cohort Study of PPP Injections for Athletes With Muscle Injury

NCT07566039
View directory record Official record
Conditions
Lower Extremity Injury
Interventions
Platelet Poor Plasma (PPP) Injection
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Englewood, Colorado • Atlanta, Georgia • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 27, 2026, 6:22 PM EDT